+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?

Ulipristal Acetate before Hysteroscopic and Laparoscopic Surgery for Uterine Myomas: Help or Hindrance?

Gynecologic and Obstetric Investigation 2018: 1-13

Ulipristal acetate ([UPA], Esmya®) is an orally active selective progesterone-receptor modulator that has been approved as preoperative treatment for uterine myomas. This systematic review aims to summarize the available data on surgical outcomes of patients undergoing myomectomy by hysteroscopy or by laparoscopy after preoperative treatment with UPA. this review was performed following PRISMA guidelines and was registered in PROSPERO (CRD42018092201). PubMed, EMBASE, and Medline databases were systematically searched electronically until March 2018 for keywords concerning this topic. There were included only peer-reviewed, English language journal articles. two prospective studies and 4 retrospective studies were included. The effect of UPA on the endometrium does not increase the technical difficulty during hysteroscopic myomectomy, but it increases the chance of complete primary resection in complex hysteroscopic myomectomies. Moreover, UPA does not increase the overall technical difficulty of laparoscopic myomectomy. Contradictory results have been reported on the impact of UPA on the separation of the myoma from the myometrium and on the consistency of the myomas. current results support the use of UPA prior to both surgical procedures. Further studies should confirm these preliminary findings and to assess the long-term outcomes of myomectomies following UPA treatment.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066010880

Download citation: RISBibTeXText

PMID: 30554215

DOI: 10.1159/000495347

Related references

Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 192: 22-26, 2016

Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 205: 43-47, 2017

Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas. Journal of Minimally Invasive Gynecology 25(7): 1274-1280, 2018

Adverse symptoms during short-term use of ulipristal acetate in women with uterine myomas and/or adenomyosis. Journal of Obstetrics and Gynaecology Research 2019, 2019

Ulipristal acetate before high complexity endoscopic (hysteroscopic, laparoscopic) myomectomy - a mini-review. Przeglad Menopauzalny 15(4): 202-204, 2017

Unexpected uterine leiomyosarcoma in a woman with multiple myomas treated with ulipristal acetate: case report and literature review. Gynecological Endocrinology 34(3): 192-194, 2017

Repeated two cycles of ulipristal acetate treatment improve the quality of life in premenopausal women with heavy menstrual bleeding dependent on uterine myomas, without impairment of bone health. Gynecological Endocrinology 2019: 1-6, 2019

Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation. Gynecologic and Obstetric Investigation 83(5): 443-454, 2017

Unexpected Uterine Leiomyosarcoma During Laparoscopic Hysterectomy Treated 6 Months With Ulipristal Acetate and Contained Power Morcellation. Journal of Minimally Invasive Gynecology 24(2): 198, 2016

Laparoscopic Myomectomy with Temporary Bilateral Uterine Artery Occlusion Compared with Traditional Surgery for Uterine Myomas: Blood Loss and Recurrence. Journal of Minimally Invasive Gynecology 25(3): 434-439, 2017

Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas. Gynecologie, Obstetrique, Fertilite and Senologie 46(10-11): 671-672, 2018

Ulipristal Acetate in Myomectomy Optimization in an Infertile Patient with Giant Myomas. Case Reports in Medicine 2016: 5135780, 2016

Addition of laparoscopic uterine nerve ablation to laparoscopic bipolar coagulation of uterine vessels for women with uterine myomas and dysmenorrhea. Journal of the American Association of Gynecologic Laparoscopists 8(4): 573-578, 2001

Successful treatment of uterine artery pseudoaneurysm with laparoscopic temporary clamping of bilateral uterine arteries, followed by hysteroscopic surgery. Journal of Obstetrics and Gynaecology Research 43(8): 1356-1359, 2017

Vaginal expulsion of submucous myomas after laparoscopic-assisted uterine depletion of the myomas. Journal of the American Association of Gynecologic Laparoscopists 8(2): 267-271, 2001